2 Matching Annotations
  1. Aug 2021
    1. Periodic Limb Movements of Sleep measurementsconfirmedthat ULDNallowed equivalent control of limb movements at half the prior dose of D2/3 agonists. Although the naltrexone dosewas 0.15 ug, the effect was retained at 100 ug and 1 mg(Bear and Kessler, 2014a,2014b).Thus, naltrexone proved effective forRLS, putativelyby facilitating sensitization of D2/3 agonists.

      The sources are patents. 2014a and 2014b.

      It is interesting that the benefits were retained over a large dose range. Oddly, full LDN doses (when combined with benzos) can help treat tardive dyskinesia. Thus, it seems plausible that the benefits for RLS are retained at even higher doses. I've not yet checked the sources to see if higher doses were tested. That is, doses over 1 mg. I doubt they were, because it would probably have been mentioned here.

  2. May 2021
    1. Systemic administration of ultra-low doses of naltrexone (16.7, 20.0, and 25.0 ng/kg) with morphine (1.0 mg/kg) extended the duration of the morphine-induced conditioned place preference.

      This is important because it suggests mood-brightening. Contrast this with combining L-type calcium channel blockers with opioids, which appears to limit tolerance to opioid analgesia that does not correspond to mood brightening.